Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 16;25(1):178.
doi: 10.1186/s12889-025-21437-9.

The effect between metabolic syndrome and life expectancy after cancer diagnosis: Catalan cohort study

Tomàs López-Jiménez  1   2 , Oleguer Plana-Ripoll  3   4 , Talita Duarte-Salles  1   5 , Anna Palomar-Cros  1   6 , Diana Puente  7   8
Affiliations

The effect between metabolic syndrome and life expectancy after cancer diagnosis: Catalan cohort study

Tomàs López-Jiménez et al. BMC Public Health. .

Abstract

This study examines remaining life expectancy (RLE) after a cancer diagnosis, focusing on age, sex, cancer type, and metabolic syndrome (MS) components, using data from the SIDIAP database in Catalonia (2006-2017). RLE was analyzed for 13 cancer types, stratified by sex and MS components. The cohort study includes 183,364 individuals followed from diagnosis until death, transfer, or study end (December 2017). RLE at age 68 (median diagnosis age) was calculated based on MS components (0, 1, 2, and ≥ 3). Men aged 68 with 0 MS components had an RLE of 13.2 years, compared to 8.9 years for those with ≥ 3 MS. Women had an RLE of 15.9 years with 0 MS components versus 11.4 years with ≥ 3 MS. RLE varied by cancer type, with the highest RLE in men seen in prostate cancer and in women in non-Hodgkin lymphoma. The lowest RLE for both sexes was in pancreatic cancer. The largest differences between 0 and ≥ 3 MS components were observed in non-Hodgkin lymphoma and the smallest in pancreatic cancer. Increased MS components were associated with reduced RLE in at least 8 cancer types for men and 9 for women. Prevention strategies targeting MS components could increase RLE in cancer patients.

Keywords: Cancer; Metabolic syndrome; Remaining life expectancy; Survival.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: This study adheres to both national and international guidelines, including the Declaration of Helsinki and Principles of Good Research Practice. In compliance with European and Spanish laws regarding confidentiality and data protection ([EU] 2016/679), all data within SIDIAP is consistently pseudo-anonymized. Hence, obtaining consent from the participants was deemed unnecessary and was waived by the Clinical Ethics Committee at IDIAPJGol. To establish a connection with the CMBD database, SIDIAP utilizes a third-party service to maintain confidentiality. Approval for the study protocol was granted by the Clinical Research Ethics Committee of IDIAPJGol (P17/212) on November 29, 2017. Anonymity and confidentiality of data and medical records were ensured throughout, following the guidelines outlined in the Organic Law 15/1999 on the Protection of Personal Data ( http://www.boe.es/boe/dias/1999/12/14/pdfs/A43088-43099.pdf ). Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Remaning life expectancy (and Life of Years Lost) by cancer type in women
Fig. 2
Fig. 2
Remaning life expectancy (and Life of Years Lost) by cancer type in men
Fig. 3
Fig. 3
Women with Cancer. Kaplan-Meier Curve by MS
Fig. 4
Fig. 4
Men with Cancer. Kaplan-Meier Curve by MS
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Blanc-Lapierre A, Spence A, Karakiewicz PI, Aprikian A, Saad F, Parent ME. Metabolic syndrome and prostate cancer risk in a population-based case-control study in Montreal. Canada BMC Public Health. 2015;15:913. - PMC - PubMed
    1. Xia B, He Q, Pan Y, Gao F, Liu A, Tang Y, Chong C, Teoh AYB, Li F, He Y, Zhang C, Yuan J. Metabolic syndrome and risk of pancreatic cancer: a population-based prospective cohort study. Int J Cancer. 2020;147(12):3384–93. - PubMed
    1. Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care. 2012;35(11):2402–11. - PMC - PubMed
    1. Montella M, Di MM, Crispo A, Grimaldi M, Bosetti C, Turati F, Giudice A, Libra M, Serraino D, La Vecchia C, Tambaro R, Cavalcanti E, Ciliberto G, Polesel J. Metabolic syndrome and the risk of urothelial carcinoma of the bladder: a case-control study. BMC Cancer. 2015;15:720. - PMC - PubMed
    1. Engin A. The definition and prevalence of obesity and metabolic syndrome. Adv Exp Med Biol. 2017;960:1–17. - PubMed

LinkOut - more resources